Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
PK150 (Sorafenib Analog)
25
CHF
CHF 25.00
In stock
AG-CR1-0162-M0011 mgCHF 25.00
AG-CR1-0162-M0055 mgCHF 50.00
AG-CR1-0162-M02525 mgCHF 135.00
| Product Details | |
|---|---|
| Synonyms | Antibiotic PK150; 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)urea |
| Product Type | Chemical |
| Properties | |
| Formula |
C15H8ClF5N2O3 |
| MW | 394.7 |
| CAS | 2165324-62-7 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (25mg/ml). |
| Identity | Determined by 1H-NMR. |
| InChi Key | SHPYXCLUNMOJOB-UHFFFAOYSA-N |
| Smiles | O=C(NC1=CC(OC(F)(F)O2)=C2C=C1)NC3=CC=C(Cl)C(C(F)(F)F)=C3 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Analog of the anticancer drug sorafenib.
- PK150 is a potent antibiotic. It shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively.
- PK150 did not induce in vitro resistance and shows oral bioavailability and in vivo efficacy. The mode of action includes the interference with menaquinone biosynthesis by inhibiting demethylmenaquinone methyltransferase and the stimulation of protein secretion by altering the activity of signal peptidase IB.
Product References
- Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms: P. Le, et al.; Nat. Chem. 12, 145 (2020)
Related Products
